Wet AMD

Biosimilar

Diabetic Eye Awareness

Diabetic Macular Edema

Diabetic Retinopathy

Geographic Atrophy

Imaging

Inherited Retinal Diseases

Europe

Ophthalmology

Retina Technology

Retinal Surgery

Uveitis

News

All News

Blogs

Media

All Videos

Case-Based Roundtable Series

Expert Interviews

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Conference

Conference Coverage

Conference Listing

Publications

Modern Retina Digital Edition

Supplements And Featured Publications

Resources

Between the Lines

CME/CE

EYLEA 8mg for nAMD and DME Treatment

Partners

Subscribe

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Modern Retina | Ophthalmology News, Events & Expert Insights

Facebook

LinkedIn

Spotlight

Clinical

1rem

Authors

A new Chinese report recognized that social media smartphone application–based interventions significantly improved follow-up adherence and increased parental knowledge among families of children with congenital ectopic lentis,

 according to Yiyuan Ma, MD, who is from the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

The disease is most often attributed to disorders that disrupt the fibrillin-rich microfibrils of the ciliary zonule, affecting its structure and function. Ectopia lentis usually results in reduced visual acuity due to induced refractive error in the first instance. The most common causes of ectopia lentis include Marfan syndrome and related type-1 fibrillinopathies, trauma, homocystinuria, and Weill–Marchesani syndrome. In addition to the refractive effects, subluxation or luxation can lead to sectoral shallowing of the anterior chamber, subluxation of the lens into the anterior chamber, and glaucoma.

Ma and colleagues emphasized that ectopic lentis requires rigorous postoperative follow-up to reduce the risk of severe complications. However, follow-up rates often can be suboptimal, indicating an urgent need for effective interventions to improve adherence.

To fill this gap, the investigators assessed the effect of WeChat (Tencent Holdings Ltd.), a social media smartphone communication application, which delivers telephone reminders and health education to improve the families’ adherence to postoperative follow-up of children with congenital ectopic lentis.

They conducted a randomized clinical trial (

) at the Zhongshan Ophthalmic Center, a tertiary ophthalmic hospital in Guangzhou that included families with children who were scheduled for lens surgery to address congenital ectopic lentis. The families were randomized to either the social media group of the standard care group.

The parents were contacted before the scheduled appointments at 1 week and 1 and 3 months postoperatively, and at those times those randomized to the social media intervention group received phone reminders and health education via the smartphone application. The main outcome was the follow-up attendance at 3 months postoperatively.

The study included 110 children (58.2% males) divided equally into 2 study groups.

The investigators reported, “The intervention group exhibited higher attendance rates than the standard-care group across all three postoperative follow-up visits (3 months: 83.6% vs 41.8%; 1 month: 81.8% vs 58.2%; and 1 week: 92.7% vs 87.3%, respectively).” The difference at the 3-month evaluation reached significance (

The children in the social media group also had greater improvements in the accurate parental knowledge about congenital ectopic lentis (10.6%, 95% CI, 7.8%-13.5%) and higher rates of amblyopia treatments (RR, 2.40; 95% CI, 1.26-4.56).

“The results of this randomized clinical trial reveal that social media smartphone application–based interventions significantly improved follow-up adherence and increased parental knowledge among families of children with congenital ectopic lentis. These findings suggest that integrating mobile health technologies into standard care can enhance the management of progressive pediatric conditions with systemic risks, ultimately improving clinical outcomes,” Ma and colleagues concluded.

Ma Y, Zhang X, Jin L, et al. Social media interventions and postoperative follow-up in congenital ectopia lentis. A randomized clinical trial. 

 Published online April 10, 2025. doi:10.1001/jamaophthalmol.2025.0526

Xu P, Ng K, Jin L, et al. Visual prognosis and complications of congenital ectopia lentis: study protocol for a hospital-based cohort in Zhongshan Ophthalmic Center. 

Lambert SR, Lyons CJ, eds. The lens. Taylor and Hoyt’s Pediatric Ophthalmology and Strabismus. 2017;Chapter 36, 5th ed., pp.337-345.e1; Elsevier, Amsterdam, the Netherlands; https://doi.org/10.1016/B978-0-7020-6616-0.00036-0

Canonical

Effect of social media on follow-up in congenital ectopia lentis

Eyestem Research announced positive results from its phase 1 trial (

) evaluating its investigational drug product, Eyecyte-RPE, in patients with 

dry age-related macular degeneration (AMD).

 in its trial in August 2024. The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts. The 3 dose levels were Eyecyte-RPE at 100,000; 200,000; and 300,000 cells. Eyecyte-RPE is a suspension of hiPSCs (human induced pluripotent stem cells) derived retinal pigment epithelial (RPE) cells.

The company stated that no serious adverse events were reported across all 3 cohorts, and the first 6 patients had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post-transplantation. The company also noted that “retinal imaging scans revealed early signs of disease reversal in a handful of patients.”

Jogin Desai, founder and CEO of Eyestem commented on the results in a press release from the company.

“The substantial vision improvement, sustained over a 4-6-month period in all 6 patients, combined with an excellent safety profile, has been very encouraging and has the potential to reshape the landscape of GA treatment globally. It is especially rewarding to see the improvement in the quality of life in these patients. We look forward to exploring these early results further in our phase two study in India and the US," said Desai.

Eyestem plans to present data from the trial at the upcoming ARVO 2025 annual meeting.

Eyestem’s Eyecyte-RPE trial shows vision rescue for geographic atrophy patients. Published April 14, 2025. Accessed April 14, 2025. 

https://economictimes.indiatimes.com/small-biz/sme-sector/eyestems-eyecyte-rpe-trial-shows-vision-rescue-for-geographic-atrophy-patients/articleshow/120271413.cms

Safety & efficacy of Eyecyte-RPE™ in patients with geographic atrophy secondary to dry age-related macular degeneration. NCT06394232. Accessed April 14, 2025. 

https://clinicaltrials.gov/study/NCT06394232

Eyecyte-RPE is a suspension of human induced pluripotent stem cells derived from retinal pigment epithelial cells.

clinical

Eyestem reports promising phase 1 trial results in patients with geographic atrophy

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) from Regeneron for the high-dose (HD) formulation of aflibercept (EYLEA HD).

The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following 

, and for broadening the dosing schedule to include every 4-week, or monthly, dosing across approved indications. The company noted that the FDA target action date is August 19, 2025, following the use of a priority review voucher.

The HD formulation is a longer-acting version of the original aflibercept drug, and through less frequent injection, it is designed to be more convenient to the patient, reducing treatment burden. In August 2023, data from Regeneron’s Phase III PULSAR trial confirmed that even at dosing intervals at least 12 weeks long, high-dose Eylea did not sacrifice vision gains while also helping patients maintain their treatment schedules.

The sBLA is supported by data from the phase 3 QUASAR trial investigating EYLEA HD in RVO. As 

showed that it met its primary endpoint at 36 weeks, with both groups of EYLEA HD patients dosed every 8 weeks achieving non-inferior visual acuity gains compared to those receiving EYLEA (aflibercept) Injection 2 mg dosed every 4 weeks.

The safety profile of EYLEA HD in the QUASAR trial was similar to EYLEA and remained generally consistent with the known safety profile of EYLEA HD in its pivotal trials. The company did note that increased ocular pressure (5%) was the only ocular treatment-emergent adverse event that occurred in ≥5% of all EYLEA HD patients, compared to 1.7% of EYLEA patients.

Regeneron has also filed an application with the FDA for the use of pre-filled syringes (PFS) of high-dose aflibercept in the US. Approval and launch of these PFSs are expected by mid-2025.

 Additionally, Bayer announced the submission of an application to the European Medicines Agency (EMA) seeking to expand the indication for aflibercept 8mg. Aflibercept is being jointly developed by Bayer and Regeneron.

EYLEA HD (aflibercept) injection 8 mg sBLA accepted for FDA Priority Review for both the treatment of macular edema following retinal vein occlusion (RVO) and for monthly dosing in approved indications. Published April 17, 2025. Accessed April 17, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-sbla-accepted-fda-priority

FDA Action Alert: Regeneron, Sanofi and Abeona. BioSpace. April 14, 2025. Accessed April 15, 2025. 

https://www.biospace.com/fda/fda-action-alert-regeneron-sanofi-and-abeona

Harp M. Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg. 

 Published February 10, 2025. Accessed April 17, 2025. 

https://www.ophthalmologytimes.com/view/regeneron-reveals-positive-results-from-multiple-trials-evaluating-eylea-hd-aflibercept-injection-8-mg

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference. Regeneron. January 13, 2025. Accessed April 15, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-business-updates-and-highlights-broad/

Hayes, H. Bayer files EMA application for aflibercept 8mg in third indication, retinal vein occlusion. 

 April 9, 2025. Accessed April 14, 2025. 

https://www.modernretina.com/view/bayer-files-ema-application-for-aflibercept-8mg-in-third-indication-retinal-vein-occlusion

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.

FDA accepts Regeneron's sBLA for Eylea HD as priority review

Regeneron has proposed a longer dosing duration for the high-dose (HD) formulation of aflibercept (EYLEA HD). The FDA is expected to release is decision on this dosing duration by April 20, 2025.

This dosing extension information was shared during Regeneron’s presentation at the J.P. Morgan Healthcare Conference in January of 2025, noting that at the time of the presentation FDA was already reviewing its application for 24-week dosing for Eylea HD in wet age-related macular degeneration (AMD) and diabetic macular edema (DME). 

The company has also filed an application with the FDA for the use of pre-filled syringes (PFS) of high-dose aflibercept with the US. Approval and launch of these PFS is expected by mid-2025.

It was also during this conference that the company noted that there are plans to submit a supplemental biologics license application (sBLA) for high-dose aflibercept with an up to 8-week dosing schedule for retinal vein occlusion (RVO). This comes after the completion of the phase 3 QUASAR trial of aflibercept 8 mg (EYLEA HD), which met its primary endpoint, in December of 2024.

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch, and hemiretinal vein occlusions. In the trial, patients were treated with an 8-week dosing regimen of EYLEA HD, following 3 or 5 initial monthly doses, while EYLEA patients were treated every 4 weeks.

Bayer announced the submission of an application to the European Medicines Agency (EMA) seeking to expand the indication for aflibercept 8mg. Aflibercept is being jointly developed by Bayer and Regeneron.

The HD formulation is a longer-acting version of the original aflibercept drug and through less frequent injection, it is designed to be more convenient to the patient, reducing treatment burden. In August 2023, data from Regeneron’s Phase III PULSAR trial confirmed that even at dosing intervals at least 12 weeks long, high-dose Eylea did not sacrifice vision gains while also helping patients maintain their treatment schedules.

Positive 3-year results were shown from an extension study of the phase 3 PULSAR trial. According to the company, the longer-term wet age-related macular degeneration (wAMD) data demonstrated the vast majority of EYLEA HD patients who entered the extension study sustained the visual gains and anatomic improvements achieved by the end of the second year, while also achieving substantially longer treatment intervals. Additionally, patients who switched from EYLEA Injection 2 mg to EYLEA HD at the beginning of the third year were also able to maintain vision and anatomic improvements through the end of the third year, but with longer dosing intervals and fewer injections.

FDA Action Alert: Regeneron, Sanofi and Abeona. BioSpace. April 14, 2025. Accessed April 15, 2025. 

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference. Regeneron. January 13, 2025. Accessed April 15, 2025. https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-business-updates-and-highlights-broad/

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion. Press Release; December 17, 2024. Accessed April 15, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-phase-3-trial-meets-primary

Hayes, H. Bayer files EMA application for aflibercept 8mg in third indication, retinal vein occlusion. 

 April 9, 2025. Accessed April 14, 2025. https://www.modernretina.com/view/bayer-files-ema-application-for-aflibercept-8mg-in-third-indication-retinal-vein-occlusion

Harp, MD. Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg. 

 February 10, 2025. Accessed April 15, 2025. https://www.modernretina.com/view/regeneron-reveals-positive-results-from-multiple-trials-evaluating-eylea-hd-aflibercept-injection-8-mg

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA

Opthea announced results from COAST, its phase 3 clinical trial in patients with 

wet age-related macular degeneration (wet AMD)

COAST (Combination OPT-302 with Aflibercept Study) evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD. According to the company, the trial did not meet its primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52.

In wet AMD patients with minimally classic and occult lesions, participants receiving sozinibercept combination therapy with a dosing regimen of every 4 weeks (n=296) or every 8 weeks (n=297) achieved a mean change in BCVA of 13.2 or 13.2 letters from baseline to week 52, respectively, compared to 13.8 letters with aflibercept monotherapy (n=299).

In the overall population, participants receiving sozinibercept combination therapy with a dosing regimen of every 4 weeks (n=333) or every 8 weeks (n=330) achieved a mean change in BCVA of 13.5 and 12.8 letters from baseline to week 52, respectively, compared to 13.7 letters with aflibercept monotherapy (n=330).

The company noted in a press release that following the negative results, the company has been assessing its rights and obligations under its Development Funding Agreement (DFA) with the investors under the DFA, among others. The company stated that it is possible that under the DFA, it could become required to pay amounts to the DFA investors that would have a material adverse impact on the solvency of the company.

Furthermore, it was stated that certain instances and events may result upon the termination of the DFA, which would result in Opthea paying DFA investors up to 4 times the amounts paid to the company under the DFA. Termination of the DFA can be triggered by the inability of Opthea to fund development costs, failure by Opthea to continue to use commercially reasonable efforts to develop sozinibercept, Opthea’s insolvency, or disagreement with the DFA investors, among other events.

The company noted that its board of directors has been in active discussions with the DFA investors to explore possible options for the company “in respect of its clinical trial program and with a view to identifying whether there is a pathway that represents the best outcome for the company and its shareholders.”

Opthea also stated that at this stage, no decision has been taken with respect to either trial (COAST or ShORe), including whether to discontinue activities for the COAST trial or accelerate and unmask the ShORe trial.

The company stated in the press release that “there remains material uncertainty as to Opthea's ability to continue as a going concern.”

Opthea announces COAST phase 3 trial topline results. Opthea. Published March 24, 2025. Accessed March 24, 2025. 

https://ir.opthea.com/news-releases/news-release-details/opthea-announces-coast-phase-3-trial-topline-results

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies

Video content above is prompted by the following:

If TKIs become available, how would this impact the relative benefits of PDS?

Panelists explore how the introduction of tyrosine kinase inhibitors (TKIs) could affect the perceived benefits of the port delivery system, as these agents may offer an alternative approach to reducing injection burden while potentially providing broader therapeutic effects.

Sponsored by Biogen

Articles

Latest Updated Articles